Palisade Bio, Inc.
General ticker "PALI" information:
- Sector: Health Care
- Industry: Biotechnology
- Capitalization: $8.9M (TTM average)
Palisade Bio, Inc. follows the US Stock Market performance with the rate: 4.9%.
Estimated limits based on current volatility of 4.2%: low 1.43$, high 1.56$
Factors to consider:
- Total employees count: 14 (+75.0%) as of 2025
- Company does not operate outside US (retrieved using AI)
- Top business risk factors: Clinical trial failure, Regulatory and compliance, Insufficient capital, Market acceptance, Manufacturing supply
- Price in estimated range
- Earnings for 6 months up through Q2 exceed our estimates
Stock Forecast*
* forecast is subjective and experimental, should not be used for any investment decisions
Long term estimates were made for the period from 2025-12-31 to 2027-12-31
- 2025-12-31 to 2026-12-31 estimated range: [1.11$, 3.84$]
- 2026-12-31 to 2027-12-31 estimated range: [0.64$, 2.35$]
Financial Metrics affecting the PALI estimates:
- Positive: with PPE of -1.5 at the end of fiscal year the price was neutral
- Negative: negative Operating income
- Negative: negative Operating cash flow
- Negative: negative Net income
- Negative: negative Industry operating cash flow (median)
- Negative: negative Industry operating income (median)
- Negative: Investing cash flow per share per price, % of 0 <= 2.08
- Negative: Shareholder equity ratio, % of 96.31 > 81.92
- Negative: -0.37 < Inventory ratio change, % of 0
- Negative: 0 < Interest expense per share per price, % of 0.01
- Negative: Industry earnings per price (median), % of -15.99 <= 0
Short-term PALI quotes
Long-term PALI plot with estimates
Financial data
| YTD | 2023-12-31 | 2024-12-31 | 2025-12-31 |
|---|---|---|---|
| Operating Revenue | $0.25MM | $0.00MM | $0.00MM |
| Operating Expenses | $13.32MM | $14.86MM | $18.06MM |
| Operating Income | $-13.07MM | $-14.86MM | $-18.06MM |
| Non-Operating Income | $0.77MM | $0.42MM | $1.27MM |
| Interest Expense | $0.01MM | $0.01MM | $0.01MM |
| R&D Expense | $6.89MM | $9.06MM | $10.19MM |
| Income(Loss) | $-12.30MM | $-14.44MM | $-16.78MM |
| Net Income(Loss)* | $-12.30MM | $-14.44MM | $-16.78MM |
| Stockholders Equity | $11.31MM | $7.49MM | $129.38MM |
| Assets | $14.05MM | $10.88MM | $134.34MM |
| Operating Cash Flow | $-11.13MM | $-12.19MM | $-10.85MM |
| Capital expenditure | $0.00MM | $0.00MM | $0.00MM |
| Investing Cash Flow | $-0.00MM | $0.00MM | $0.00MM |
| Financing Cash Flow | $11.19MM | $9.58MM | $134.44MM |
| Earnings Per Share** | $-26.97 | $-10.20 | $-0.30 |
* Profit(Loss) attributable to entity.
** EPS are Split Adjusted, recent splits may be reflected with a delay.